Log in
Enquire now
Anacor Pharmaceutical

Anacor Pharmaceutical

A biopharmaceutical company that develops small-molecule therapeutics to treat fungal, bacterial, and inflammatory diseases

OverviewStructured DataIssuesContributors

Contents

anacor.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Healthcare
Healthcare
Pharmaceutical industry
Pharmaceutical industry
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Location
Palo Alto, California
Palo Alto, California
B2X
B2B
B2B
0
AngelList URL
angel.co/anacor-pharmaceutical
Number of Employees (Ranges)
51 – 200
Full Address
1020 East Meadow Circle, Palo Alto, CA 94303-4230, US
CIK Number
1,411,158
Place of Incorporation
Delaware
Delaware
Investors
Rho Capital Partners
Rho Capital Partners
‌
Schering
Venrock
Venrock
Red Abbey Venture Partners
Red Abbey Venture Partners
DUNS Number
128824484
IRS Number
251,854,385
Founded Date
2002
Total Funding Amount (USD)
130,000,000
Latest Funding Round Date
April 9, 2013
Acquisition Transaction
‌
Acquisition of Anacor Pharmaceutical by Pfizer
Latest Funding Type
Series E
Series E
CAGE Code
3AYC5
Patents Assigned (Count)
54
Wellfound ID
anacor-pharmaceutical
Country
United States
United States

Other attributes

Acquirer
Pfizer
Pfizer
Company Operating Status
Active
Previous Name
Anacor Pharmaceuticals Inc
Public/Private
Public
SIC Code
2,834
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Anacor Pharmaceutical

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.